ElectroCore Inc

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ElectroCore reports record revenue growth and strategic expansion plans

ElectroCore's Q1 2024 earnings call showcased impressive revenue growth, strong gross margins, and successful product launches, underlining the company's market resilience and innovation capabilities. With a focus on strategic expansion and profitability, ElectroCore is well-positioned for sustained growth and market leadership.
While facing challenges in managing R&D expenses and optimizing product returns, ElectroCore's commitment to operational efficiency and market diversification mitigates potential risks. The company's emphasis on employee contributions and customer relationships reinforces its competitive edge and customer loyalty.
By capitalizing on opportunities to expand product offerings, enter new markets, and drive innovation, ElectroCore can unlock significant growth potential and solidify its position as a key player in the neuromodulation industry. Navigating challenges through strategic decision-making and market differentiation will be crucial for ElectroCore's future success.

ElectroCore reports record revenue and margin growth in Q2 2024

ElectroCore's Q2 2024 earnings call showcased exceptional financial performance, marked by record revenue, improved margins, and a notable reduction in net loss.
The company's strengths lie in its revenue growth, product innovation, and solid financial position, while facing challenges in certain product sales and market competition.
Opportunities for ElectroCore include expanding product reach, exploring new therapeutic areas, and leveraging its strong cash position for strategic investments and growth.
Overall, ElectroCore's performance reflects resilience and potential for sustained growth in the healthcare industry, supported by a strong financial foundation and innovative product pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROCKAWAY, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that “SUNCT/ SUNA with neurovascular conflict: consider nVNS,” will be presented at the American Headache Society's 65th Annual Scientific Meeting on June 16-17, 2023 in Austin, Texas.

electroCore Announces Poster to be Presented at the American Headache Society's 65th Annual Scientific Meeting

ROCKAWAY, N.J., May 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the resignation of its Founder and former CEO, JP Errico from the Board of Directors. Mr. Errico will continue as a consultant and strategic advisor to the Company, focused on supporting the growth and direction of the wellness and human performance brands, Truvaga™ and TAC-STIM™.

electroCore, Inc. Announces Departure of JP Errico from the Board of Directors

ROCKAWAY, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore's Chief Executive Officer, Dan Goldberger, will present at the 13th Annual LD Micro Invitational XIII in Los Angeles, California from June 6-8, 2023.

electroCore to Participate at 13th Annual LD Micro Invitational XIII

electroCore, Inc. (NASDAQ:ECOR ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Nicole Jones - IR Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Small-Cap Research Ramakanth Swayampakula - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Nick Sherwood - Maxim Group Operator And welcome to the electroCore First Quarter 2023 Earnings Call.

electroCore, Inc. (ECOR) Q1 2023 Earnings Call Transcript

Record first quarter 2023 net sales of $2.8 million, approximately 46% over first quarter 2022 Company to host a conference call and webcast today, May 3, 2023, at 4:30 PM EDT ROCKAWAY, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced first quarter 2023 financial results and provided an operational update.

electroCore Announces First Quarter 2023 Financial Results

ROCKAWAY, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore's Chief Executive Officer, Dan Goldberger, will present at the Annual Aegis Virtual Conference being held May 2-4, 2023.

electroCore to Participate at Annual Aegis Virtual Conference

ROCKAWAY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded Emory University and the Georgia Institute of Technology a 3-year, $6.0 million grant through the NIH Helping to End Addiction Long Term (HEAL) Initiative to conduct a pivotal clinical trial of gammaCore (non-invasive vagus nerve stimulator; nVNS) for the treatment of opioid use disorder (OUD).

National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore™ (nVNS) in Patients with Opioid Use Disorders

ROCKAWAY, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2023, after the close of the market on Wednesday, May 3, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.

electroCore to Announce First Quarter Financial Results on Wednesday, May 3

ROCKAWAY, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today provided select preliminary unaudited financial guidance for the first quarter of 2023.

electroCore Provides Select First Quarter 2023 Financial Guidance

ROCKAWAY, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Teijin Limited (Teijin), a global conglomerate based in Japan offering advanced solutions in healthcare, materials and information technology, has remitted payment of the annual fee under its license agreement with the Company for certain exclusive rights to the Company's non-invasive vagus nerve stimulation (nVNS) technology for commercialization in Japan for a range of primary headache disorders.

electroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan

ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a license to import, distribute and market gammaCore Sapphire™, non-invasive vagus nerve stimulator (nVNS) in Indonesia. This follows the equivalent license approvals received in Malaysia in September 2022 and in South Africa in March 2023.

electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa

ROCKAWAY, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it does not have direct exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank. electroCore does not hold cash deposits or securities with these banking institutions, and currently holds corporate cash accounts with large global money center banks.

electroCore Affirms No Direct Exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank

Poster Highlights the Ability of Non-Invasive Vagus Nerve Stimulation (nVNS) to Accelerate Learning of a Second Language Poster Highlights the Ability of Non-Invasive Vagus Nerve Stimulation (nVNS) to Accelerate Learning of a Second Language

electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting

electroCore, Inc. (NASDAQ:ECOR ) Q4 2022 Results Conference Call March 8, 2023 4:30 PM ET Company Participants Nicole Jones - IR Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann John Vandermosten - Zacks Small-Cap Research Ramakanth Swayampakula - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Hello, and welcome to the electroCore Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast [Operator Instructions].

electroCore, Inc. (ECOR) Q4 2022 Earnings Call Transcript

Record full year 2022 net sales of $ 8.6 million increased 58 % over $ 5.5 million for full year 2021

electroCore Announces Fourth Quarter and Full Year 2022 Financial Results

Carvana

Genius Brands

Lannett Company

Marathon Digital Holdings

Rocket Companies, Inc.

Getty Images Holdings Inc

With major economic weakness possibly lurking around the corner, investors should consider targeting stocks to sell. Specifically, market participants should note securities that feature rising short borrow fees.

7 Stocks to Sell as Borrowing Costs Rise

ROCKAWAY, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority's Technology Business Tax Certificate Transfer program. As a result, the Company has received approximately $211,000 in non-dilutive cash from the sale of these net operating loss (NOL) tax benefits. “We appreciate the support from the state of New Jersey through its NOL program, which we have benefited from over the past few years,” stated, Brian Posner, Chief Financial Officer of electroCore. “This non-dilutive funding will continue supporting us as we invest in our growing business. We appreciate the support of New Jersey state leadership and the New Jersey Economic Development Authority, which has provided us with approximately $2.7 million of non-dilutive funding over the last three years.” The New Jersey Technology Business Tax Certificate Transfer program enables qualified, unprofitable NJ-based technology or biotechnology companies with fewer than 225 US employees (including parent company and all subsidiaries) to sell a percentage of their NOL and research and development tax credits to unrelated profitable corporations. NOLs may be sold for at least 80 percent of their value, up to a maximum lifetime benefit of $20 million per business. This allows qualifying technology and biotechnology companies with NOLs to turn tax losses and credits into cash proceeds to fund their growth and operations, including research and development or other allowable expenditures. About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving outcomes through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets. For more information, visit www.electrocore.com. Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding electroCore's business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally, and other statements that are not historical in nature, particularly those using terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize our products, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov. Contact: Rich CockrellCG Capital404-736-3838 ecor@cg.capital

electroCore Completes Sale of New Jersey Tax Benefits

ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-15. The reverse stock split will take effect as of 12:01 a.m. ET, on Wednesday, February 15, 2023, and shares of electroCore will trade on a post-split basis on the Nasdaq Capital Market under the existing trading symbol, “ECOR,” at the market open on February 15, 2023. At the Company's special meeting of stockholders held February 13, 2023, stockholders approved an amendment to the Company's certificate of incorporation to implement a reverse stock split in a range of 1-for-5 to 1-for-50 and granted the board of directors the authority to implement and determine the exact split ratio within such range, which was set by the board at 1-for-15. Following the reverse stock split, the new CUSIP number of the common stock will be 28531P202, with the par value per share of common stock remaining at $0.001. A proportionate adjustment will be made to the per-share exercise prices and number of shares issuable under all outstanding warrants and equity awards. When the reverse stock split becomes effective, every 15 shares of the Company's issued and outstanding common stock will be combined into one share of common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will instead receive a cash payment based on the closing sales price of the Company's common stock on the Nasdaq Capital Market on February 14, 2023. Each stockholder's percentage ownership interest in electroCore will remain unchanged after the reverse stock split (other than the de minimis impact from the elimination of the fractional shares). The Company is implementing the reverse stock split to seek to increase the price of its common stock on the Nasdaq Capital Market and potentially regain compliance with the minimum bid price requirement of $1.00 per share for a minimum of 10 consecutive trading days, as required for continuing listing of the common stock on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Company has appealed the December 20, 2022, determination letter from the Nasdaq Stock Market LLC (“Nasdaq”) that the common stock has not achieved compliance with the Bid Price Rule. A hearing was held on February 2, 2023, before a Nasdaq Hearings Panel (the “Panel”). While the appeal process is pending, the potential suspension of trading of the common stock by Nasdaq is stayed, a Form 25-NSE will not be filed with the Securities and Exchange Commission, and the common stock continues to trade on the Nasdaq Capital Market until the hearing process concludes and the Panel issues a written decision. The Company has furnished the Panel with a plan to regain compliance, part of which is the implementation of the reverse stock split in order to attempt to regain compliance with the Bid Price Rule and thereby avoid delisting of the common stock from the Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company's request for a continuing suspension of delisting or continued listing on the Nasdaq Capital Market, nor that the common stock will regain compliance with the Bid Price Rule. About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic company dedicated to improving outcomes through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets. For more information, visit www.electrocore.com.For more information, visit www.electrocore.com. Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding electroCore's business prospects and clinical and product development plans; electroCore's ability to maintain its listing on Nasdaq; marketability of the Company's stock post-reverse split; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents providing expanded IP coverage; the possibility of future business models and revenue streams from the company's potential combining of nVNS and smartphone or application-based technologies; the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those using terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov. Investors: Rich CockrellCG Capital404-736-3838 ecor@cg.capital

electroCore Announces Reverse Stock Split

ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents related to its non-invasive vagus nerve stimulation (nVNS) technology to electroCore, including the following patents:

electroCore Announces Issuance of Two New U.S. Patents

ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium.

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association

Homology Medicines

Grab Holdings Ltd

iQIYI

Porch Group

Analysts say these are penny stocks to buy but do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050%

ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Goldberger, will be conducting one-on-ones at the Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum. Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum Date:  Thursday, November 17, 2022Event: One-on-one meetings

electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum

electroCore, Inc. (NASDAQ:ECOR ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Nicole Jones - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Peter Staats - Chief Medical Officer Conference Call Participants Destiny Hance - Ladenburg Thalmann John Vandermosten - Zacks Operator Greetings and welcome to the electroCore Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

electroCore, Inc. (ECOR) Q3 2022 Earnings Call Transcript

Third quarter 2022 revenue grew 33% over third quarter 2021

News for ElectroCore Inc Stock (ECOR)